Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
Don't Buy Weight-Loss Medication From Unauthorized Sources, UK Health Agency Warns About Risks
As the New Year begins, the U.K.'s Medicines and Healthcare Products Regulatory Agency (MHRA) is urging the public to avoid purchasing weight-loss medicines without a prescription from unauthorized sources like beauty salons, social media platforms, or unverified websites.
新年伊始，英國藥品和醫療產品監管局（MHRA）敦促公衆避免從未經授權的渠道購買減肥藥物，例如美容院、社交媒體平台或未驗證的網站。
Such practices violate the law and expose individuals to significant health risks.
這種做法違反法律，並使個人面臨重大健康風險。
MHRA Deputy Director of Criminal Enforcement Andy Morling cautioned against the increasing trend of illegal weight-loss medicine sales, describing them as dangerous "quick fixes."
MHRA犯罪執法副主任安迪·莫林警告說，非法減肥藥物銷售的趨勢正在增加，形容這些藥物爲危險的"快速解決方案"。
Also Read: UK's NHS Prescribes Weight-Loss Drug Wegovy Less Than Expected Due To Service Shortages
另請閱讀：由於服務短缺，英國國民健康服務體系（NHS）對減肥藥物Wegovy的處方量少於預期
He emphasized that these medicines, known as GLP-1 receptor agonists, are potent drugs that should only be dispensed by licensed healthcare professionals. Buying them from unregulated sources puts consumers' health at serious risk and contributes to illegal activity.
他強調，這些藥物稱爲GLP-1受體激動劑，是強效藥物，應該僅由持牌醫療專業人員分發。從未受監管的渠道購買這些藥物會嚴重危害消費者的健康，並助長非法活動。
Unregulated online products may contain harmful toxins, posing serious health risks that could result in hospitalization.
未經監管的在線產品可能含有有害毒素，構成嚴重健康風險，可能導致住院治療。
Eli Lilly And Co's (NYSE:LLY) Tirzepatide and Novo Nordisk A/S (NYSE:NVO) semaglutide dominate the GLP-1 class products market.
禮來（紐交所：LLY）的 Tirzepatide 和諾和諾德（紐交所：NVO）的 semaglutide 在GLP-1類產品市場佔據主導地位。
The agency works to curb the distribution of these unapproved products by identifying and removing illegal sales posts, suspending accounts, and shutting down rogue websites.
該機構通過識別和刪除非法銷售帖子、暫停賬戶以及關閉惡意網站，努力遏制這些未經批准產品的分銷。
Chief Safety Officer Dr. Alison Cave highlighted the importance of consulting healthcare professionals before starting any treatment. Decisions about weight-loss medicines should be based on a comprehensive assessment of benefits and risks, with the patient and healthcare provider working together.
首席安全官阿莉森·凱夫博士強調了在開始任何治療之前諮詢醫療專業人員的重要性。有關減肥藥物的決策應基於對利益和風險的全面評估，並且患者與醫療提供者需要共同合作。
The MHRA continues to monitor the safety of all licensed weight-loss drugs, urging patients to report any suspected side effects through the Yellow Card scheme.
MHRA繼續監測所有獲得許可的減肥藥物的安全性，並敦促患者通過黃卡計劃報告任何可疑的副作用。
In October, NHS England proposed a phased rollout of tirzepatide.
在十月份，英格蘭國民健康服務提出了tirzepatide的分階段推出方案。
Under draft guidance from an independent committee at the National Institute for Health and Care Excellence, tirzepatide has been recommended for patients living with obesity, with a maximum list price of 122 pounds ($159.6) per month for the highest dose.
根據國家健康與護理卓越學院獨立委員會的草案指導，建議將tirzepatide用於肥胖患者，最高劑量的上市價格爲122英鎊（約159.6美元）每月。
- Gold Price Surge Pushes Rolex to Raise Prices for Iconic Watches
- 黃金價格飆升促使勞力士提高標誌性手錶的價格
Wegovy Photo by Tobias Arhelger via Shutterstock
Wegovy照片由Tobias Arhelger提供，來源於Shutterstock
譯文內容由第三人軟體翻譯。